Tilray Reports 26% Revenue Spike For 2020, Plans To Close Aphria Deal In Q2

Cannabis giant Tilray Inc. TLRY saw revenue climb to $210.5 million in 2020. That's a 26% spike compared to what the Nanaimo, Canada-based company reported for 2019.

In Tilray's earnings report published Wednesday afternoon, CEO Brendan Kennedy credited the growth to international medical sales and Canadian adult-use sales, up 191% and 49%, respectively, throughout the fourth quarter.

Tilray also reduced costs by about $57 million compared to the same three-month period in 2019.

"As a result, we now operate with a more focused, efficient and competitive cost structure," he said in a prepared statement. 

Related: Exclusive: Aphria, Tilray CEOs Discuss Merger, Hiring And 'No Massive Layoffs'

Q4 Breakdown: Tilray is currently in the midst of closing a merger with fellow Canadian cannabis company Aphria Inc. APHA. The deal should wrap in the second quarter of 2021. 

In addition, the company reported:

  • A total revenue increase of $56.6 million — up 20.5% compared to the fourth quarter of 2019
  • A cannabis segment revenue increase of 46% to $41.2 million
  • A net loss of $3 million (it lost $219.8 million for the same period in 2019)
  • Adjusted EBITDA of $2.2 million
  • Some $261.3 million in cash as of Feb. 16

A 'New' Tilray: Kennedy cited an "increasingly-favorable political environment," as well as the pending transaction with Leamington, Ontario-based Aphria, for positioning Tilray for growth.

"Finally, and as previously stated, the ‘new’ Tilray will achieve over C$100 million in anticipated pre-tax synergies," he added, touting "significant value for stockholders.”

See also: How to Buy Tilray (TLRY) Stock

In addition, the company highlighted its cross-border expansion efforts — namely in Portugal and Spain. Those recent moves allowed Tilray to make its brand of medical cannabis available in 17 countries.

Tilray's stock closed at $31.51 and traded up 10% in after-hours trading.

Courtesy image

TLRY Logo
TLRYTilray Brands Inc
$0.6123-3.89%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
5.26
Growth
21.75
Quality
N/A
Value
80.55
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Cannabis is evolving—don’t get left behind!

Curious about what’s next for the industry and how to stay ahead in today’s competitive market?

Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.

Secure your spot now before prices go up—this is where the biggest deals and connections happen!

Get your tickets today!

Comments
Loading...